Related Experiment Video
Updated: Jul 16, 2025

Establishment of a Mouse Model with Cough Hypersensitivity via Inhalation of Citric Acid
Published on: January 10, 2025
Factors influencing behavioral cough suppression therapy in children with nonspecific chronic cough
Robert Brinton Fujiki1, Miranda L Wright2,3, Amanda E Fujiki4
1Department of Surgery, University of Wisconsin - Madison, Madison, Wisconsin, USA.
Insights
Behavioral cough suppression therapy (BCST) effectively treats chronic cough in children, often resolving symptoms in just a few sessions. This low-risk therapy shows promising results for pediatric patients with nonspecific cough.
Area of Science:
- Pediatric Otolaryngology
- Speech-Language Pathology
- Behavioral Therapy
Background:
- Chronic nonspecific cough, also known as tic cough, is common in children.
- Behavioral cough suppression therapy (BCST) is a frequent treatment, but its effectiveness and duration are not well-documented.
- This study aimed to evaluate pediatric BCST outcomes and identify predictive factors.
Purpose of the Study:
- To determine the efficacy of BCST in improving chronic cough in children.
- To identify factors that predict the number of BCST sessions required.
- To characterize cough features and associated comorbidities in pediatric patients.
Main Methods:
- Retrospective observational cohort study.
- Data extracted from electronic medical records of 151 children treated at a pediatric otolaryngology clinic.
- Included cough characteristics, medical history, BCST details, and outcomes.
Main Results:
- Most coughs were dry, often preceded by a tickle, and present for an average of 19 months.
- High rates of comorbidities observed: reflux (62.3%), General Anxiety Disorder, asthma (22.1%), and disordered sleep breathing (19.2%).
- BCST reduced cough in 92.5% of patients within an average of 1.7 sessions; behavioral health diagnoses and ILS symptoms predicted more sessions.
Conclusions:
- BCST appears to be a low-risk and effective treatment for pediatric chronic nonspecific cough.
- Further investigation with randomized clinical trials is warranted.
- Understanding comorbidities and cough characteristics can inform treatment approaches.
Background:
Behavioral cough suppression therapy (BCST) with a speech-language pathologist is a common treatment for chronic nonspecific cough (a.k.a., tic cough) in children. Yet, the outcomes and duration of pediatric BCST have eluded formal investigation. This study examined whether BCST improves cough in children with nonspecific cough and factors that predict the course of treatment. Additionally, the cough characteristics and comorbidities associated with the condition were examined.
Methods:
A retrospective, observational cohort design was utilized. Cough characteristics, medical history, and BCST treatment details and outcomes for 151 children were extracted from the electronic medical record of a large outpatient pediatric otolaryngology clinic.
Results:
Cough was dry and onset unaccompanied by illness in most cases. Roughly half of patients reported gradual onset and cough proceeded by tickle. On average, patients experienced symptoms for 19 months (SD = 20.09) before diagnosis. Rates of comorbid General Anxiety Disorder were elevated compared to pediatric norms. Additionally, high rates of asthma (22.1%), reflux (62.3%), and disordered sleep breathing (19.2%) were observed. Common findings on laryngoscopy included interarytenoid edema and erythema. Vocal fold changes were observed in 22.9% of children. BCST reduced cough in 92.5% of patients following an average of 1.7 sessions. Comorbid behavioral health diagnoses (p = 0.013) or induced laryngeal obstruction symptoms (p = 0.025) were significant predictors of increased therapy sessions. Cough proceeded by tickle significantly predicted fewer sessions in therapy (p = 0.011).
Interpretation:
Although randomized clinical trials are needed, these data suggest that BCST is a low-risk, effective treatment for children with nonspecific cough.
More Related Videos
Related Concept Videos
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
COPD: Management Using Bronchodilators and Corticosteroids
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...

